The Sullivan Group
Dr. Gareth Sullivan is a PI in the Hybrid Technology Hub. He is a group leader within the Norwegian Centre for Stem Cell Research (www.garethsullivan.com) and has affiliated positions at the Institute of Immunology and the Department of Pediatric Research, Oslo University Hospital. His research focuses on understanding what dictates cellular fate decisions and the utilisation of induced pluripotent stem cells to dissect debilitating metabolic disease. Over the past 5 years the Sullivan group has developed liver models using human pluripotent stem cells. This includes the first description of an endodermal lineage (hepatoctyes) being derived from human induced pluripotent stem cells using a small molecule approach. These technologies are now being employed to unravel metabolic disease with patient specific models to gain insight into disease processes in the dish.
- Scarfe L, Brillant N, Kumar JD, Ali N, Alrumayh A, Amali M, Barbellion S and et al. Pre-clinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. Nature Regenerative Medicine. 2017: Manuscript in Press/ Accepted.
- Gamal W, Treskes P, Chesne CG, Samuel K, Sullivan GJ, Siller R, Srsen V, Underwood I, Smith S, Hayes PC, Plevris JN, Bagnaninchi PO and Nelson LJ. Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver. Scientific Reports. 2017:DOI: 10.1038/srep37541.
- Siller R, Naumovska E, Mathapati S, Lycke M and Sullivan GJ*. Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines. Scientific Reports. 2016:DOI: 10.1038/srep37178. (*corresponding author).
- Siller R, Greenhough S, Naumovska E and Sullivan GJ*. Small molecule driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015: 4:939-952. (*corresponding author).
- Siller R, Greenhough S, Park IH and Sullivan GJ*. Modelling human disease with pluripotent stem cells. Current Gene Therapy. 2013: 13:99-110. (*corresponding author).